Methyl 3-(benzylamino)-2-[1-(4-methylphenyl)sulfonylindol-3-yl]imidazo[1,2-a]pyridine-6-carboxylate
C31H26N4O4S — CID 155521560
Data last refreshed: (MolForge compound catalog, from PubChem)
About Methyl 3-(benzylamino)-2-[1-(4-methylphenyl)sulfonylindol-3-yl]imidazo[1,2-a]pyridine-6-carboxylate
Methyl 3-(benzylamino)-2-[1-(4-methylphenyl)sulfonylindol-3-yl]imidazo[1,2-a]pyridine-6-carboxylate (PubChem CID 155521560) has the molecular formula C31H26N4O4S and a molecular weight of 550.64 g/mol. Its IUPAC name is methyl 3-(benzylamino)-2-[1-(4-methylphenyl)sulfonylindol-3-yl]imidazo[1,2-a]pyridine-6-carboxylate.
Molecular Properties
| Compound Name | Methyl 3-(benzylamino)-2-[1-(4-methylphenyl)sulfonylindol-3-yl]imidazo[1,2-a]pyridine-6-carboxylate |
|---|---|
| PubChem CID | 155521560 |
| Molecular Formula | C31H26N4O4S |
| Molecular Weight | 550.64 g/mol |
| Exact Mass | 550.17 |
| IUPAC Name | methyl 3-(benzylamino)-2-[1-(4-methylphenyl)sulfonylindol-3-yl]imidazo[1,2-a]pyridine-6-carboxylate |
| SMILES | COC(=O)c1ccc2nc(-c3cn(S(=O)(=O)c4ccc(C)cc4)c4ccccc34)c(NCc3ccccc3)n2c1 |
| InChI | InChI=1S/C31H26N4O4S/c1-21-12-15-24(16-13-21)40(37,38)35-20-26(25-10-6-7-11-27(25)35)29-30(32-18-22-8-4-3-5-9-22)34-19-23(31(36)39-2)14-17-28(34)33-29/h3-17,19-20,32H,18H2,1-2H3 |
| InChIKey | XAPJUVLYEWFXSR-UHFFFAOYSA-N |
| XLogP | 5.90 |
| TPSA | 94.70 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 550.64 |
| LogP ≤ 5 | 5.90 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155521560 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.